DK1575531T3 - Terapier for kronisk inflammatorisk demyeliniserende polyneuropati under anvendelse af interferon-beta - Google Patents

Terapier for kronisk inflammatorisk demyeliniserende polyneuropati under anvendelse af interferon-beta

Info

Publication number
DK1575531T3
DK1575531T3 DK03798770.8T DK03798770T DK1575531T3 DK 1575531 T3 DK1575531 T3 DK 1575531T3 DK 03798770 T DK03798770 T DK 03798770T DK 1575531 T3 DK1575531 T3 DK 1575531T3
Authority
DK
Denmark
Prior art keywords
interferon
therapies
beta
chronic inflammatory
inflammatory demyelinating
Prior art date
Application number
DK03798770.8T
Other languages
English (en)
Inventor
Alfred Sandrock
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Application granted granted Critical
Publication of DK1575531T3 publication Critical patent/DK1575531T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
DK03798770.8T 2002-09-27 2003-09-26 Terapier for kronisk inflammatorisk demyeliniserende polyneuropati under anvendelse af interferon-beta DK1575531T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41430702P 2002-09-27 2002-09-27
PCT/US2003/030532 WO2004028472A2 (en) 2002-09-27 2003-09-26 THERAPIES FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY USING INTERFERON-β

Publications (1)

Publication Number Publication Date
DK1575531T3 true DK1575531T3 (da) 2011-11-21

Family

ID=32043377

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03798770.8T DK1575531T3 (da) 2002-09-27 2003-09-26 Terapier for kronisk inflammatorisk demyeliniserende polyneuropati under anvendelse af interferon-beta

Country Status (21)

Country Link
US (2) US20060182715A1 (da)
EP (1) EP1575531B9 (da)
JP (3) JP2006513990A (da)
KR (1) KR20050059195A (da)
CN (2) CN102038938A (da)
AT (1) ATE520412T1 (da)
AU (1) AU2003277006C1 (da)
BR (1) BR0314548A (da)
CA (1) CA2500189A1 (da)
DK (1) DK1575531T3 (da)
EA (1) EA009289B1 (da)
GE (1) GEP20094699B (da)
IS (1) IS7746A (da)
MX (1) MXPA05003243A (da)
NO (1) NO20052059L (da)
NZ (1) NZ565990A (da)
PL (1) PL377612A1 (da)
RS (1) RS20050255A (da)
UA (1) UA86749C2 (da)
WO (1) WO2004028472A2 (da)
ZA (1) ZA200502416B (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ565990A (en) * 2002-09-27 2009-10-30 Biogen Idec Inc Therapies for chronic inflammatory demyelinating polyneuropathy using interferon-beta
TW200633718A (en) * 2004-12-16 2006-10-01 Applied Research Systems Treatment of hepatitis c in the asian population
WO2008130382A2 (en) 2006-10-31 2008-10-30 East Carolina University Fusion proteins comprising an anti -inflammatory cytokine and an antigen for treatment of immune disorders
US20120082644A1 (en) 2009-03-31 2012-04-05 Mannie Mark D Cytokines and neuroantigens for treatment of immune disorders
MY168902A (en) * 2011-10-01 2018-12-04 Glytech Inc Glycosylated polypeptide and pharmaceutical composition containing same
GB201212878D0 (en) 2012-07-20 2012-09-05 Pike Justin Authentication method and system
EP3072513A1 (en) 2015-03-26 2016-09-28 Medday Biotin for treating Amyotrophic lateral sclerosis
GB201520741D0 (en) 2015-05-27 2016-01-06 Mypinpad Ltd And Licentia Group Ltd Authentication methods and systems
KR102454376B1 (ko) * 2018-07-04 2022-10-17 서울대학교산학협력단 신경손상의 면역세포치료

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0154316B1 (en) * 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
ZA878295B (en) * 1986-11-06 1988-05-03 Amarillo Cell Culture Co. Inc. Treatment of immuno-resistant disease
DE3712564A1 (de) * 1987-04-14 1988-11-24 Bioferon Biochem Substanz Verfahren zur konstruktion einer animalen zellinie fuer die herstellung von humanem interferon-beta
DE4128319A1 (de) * 1991-08-27 1993-03-04 Bioferon Biochem Substanz Neues rekombinantes human-ifn-beta, verfahren zu dessen herstellung und dieses enthaltende pharmazeutische zubereitungen
US5545723A (en) * 1994-03-15 1996-08-13 Biogen Inc. Muteins of IFN-β
IL113280A (en) * 1994-04-12 2004-12-15 Res Dev Foundation A preparation for the treatment of self-immunization diseases with the help of interferon of one type
ZA952797B (en) * 1994-04-12 1996-10-07 Res Dev Foundation Method of treating auto-immune diseases using type one interferons
TW403653B (en) * 1995-12-25 2000-09-01 Otsuka Pharma Co Ltd Dry compositions
EP2260872B1 (en) * 1998-10-16 2017-08-30 Biogen MA Inc. Polymer conjugates of interferon beta-1A and uses thereof
DE69931507T2 (de) * 1998-10-16 2007-01-11 Biogen Idec Ma Inc., Cambridge Interferon-beta fusionsproteine und deren verwendungen
US6419934B1 (en) * 1999-02-24 2002-07-16 Edward L. Tobinick TNF modulators for treating neurological disorders associated with viral infection
CA2363779A1 (en) * 1999-02-26 2000-08-31 Human Genome Sciences, Inc. Human endokine alpha and methods of use
US6531122B1 (en) * 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
WO2002036628A2 (en) * 2000-11-02 2002-05-10 Maxygen Aps New multimeric interferon beta polypeptides
EP2080771A3 (en) * 2001-02-27 2010-01-06 Maxygen Aps New interferon beta-like molecules
WO2002072019A2 (en) * 2001-03-13 2002-09-19 Vical Incorporated Interferon-beta polynucleotide therapy for autoimmune and inflammatory diseases
NZ565990A (en) * 2002-09-27 2009-10-30 Biogen Idec Inc Therapies for chronic inflammatory demyelinating polyneuropathy using interferon-beta

Also Published As

Publication number Publication date
WO2004028472A3 (en) 2006-01-19
EP1575531A2 (en) 2005-09-21
NO20052059L (no) 2005-06-27
MXPA05003243A (es) 2005-09-12
JP2007039463A (ja) 2007-02-15
AU2003277006C1 (en) 2010-04-01
EA009289B1 (ru) 2007-12-28
AU2003277006A1 (en) 2004-04-19
RS20050255A (en) 2007-08-03
EP1575531B1 (en) 2011-08-17
CA2500189A1 (en) 2004-04-08
IS7746A (is) 2005-03-15
GEP20094699B (en) 2009-06-10
JP2006513990A (ja) 2006-04-27
ZA200502416B (en) 2005-10-20
EA200500545A2 (ru) 2005-08-25
CN102038938A (zh) 2011-05-04
BR0314548A (pt) 2005-08-09
ATE520412T1 (de) 2011-09-15
EA200500545A3 (ru) 2007-04-27
PL377612A1 (pl) 2006-02-06
CN1802170A (zh) 2006-07-12
KR20050059195A (ko) 2005-06-17
EP1575531A4 (en) 2008-01-23
NZ565990A (en) 2009-10-30
US20120058083A1 (en) 2012-03-08
NO20052059D0 (no) 2005-04-27
AU2003277006B2 (en) 2009-09-10
WO2004028472A2 (en) 2004-04-08
US20060182715A1 (en) 2006-08-17
UA86749C2 (en) 2009-05-25
EP1575531B9 (en) 2012-02-22
JP2011132248A (ja) 2011-07-07

Similar Documents

Publication Publication Date Title
NO20052059D0 (no) Terapier for kronisk inflammatorisk demyeliniserende polynevropati ved anvendelse av interferon-beta.
WO2004006756A3 (en) THERAPIES FOR RENAL FAILURE USING INTERFERON-β
DK1539166T3 (da) Farmaceutiske sammensætninger indeholdende dextromethorphan og quinidin til behandling af neurologiske sygdomme
LTPA2017009I1 (lt) Brutono tirozinkinazės inhibitoriai
NO20052923L (no) Fusjonerte bicykliske nitrogeninneholdende heteroringer
ATE304017T1 (de) Oxazolylpyrazol-derivate als kinase-inhibitoren
RS51821B (en) NEW COMBINED USE OF SULFONAMIDE UNITS IN CANCER TREATMENT
EA200401284A1 (ru) Замещённые бензазолы и их применение в качестве ингибиторов киназы raf
CY1108874T1 (el) ΧΡΗΣΗ ΤΩΝ ΑΝΑΣΤΟΛΕΩΝ Ι κΒ- ΚΙΝΑΣΗΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΠΟΝΟΥ
CY1111613T1 (el) Μεθοδοι για την αντιμετωπιση της μολυνσης απο hiv
EA200602137A1 (ru) Гидрогелевые препараты интерферона
DK1781296T3 (da) Quinazolinderivater og deres anvendelse ved behandlingen af thrombocytæmi
MX2009013779A (es) Uso de agonistas de tlr y/o interferonas tipo 1 para aliviar la toxicidad de los regimenes terapeuticos de agonistas de tnf-r.
NO20043313L (no) Anvendelse av COX-2 inhibitorer i kombinasjon med antivirale midler for behandling av Papilloma virus infeksjoner
WO2007120156A3 (en) Animal models of long qt syndrome and uses thereof
SE0301654D0 (sv) Novel compounds
EA200500764A1 (ru) Фармацевтические композиции и лекарственные формы для трансбуккальной и сублингвальной доставки тизанидина и способы введения тизанидина сублингвально или трансбуккально
CY1109803T1 (el) Φαρμακευτικες συνθεσεις που βασιζονται σε ανταγωνιστες νκ2 για παιδιατρικη χρηση
DK1496918T3 (da) Anvendelse af natriummetaarsenit til behandling af tumorer
CY1105117T1 (el) Θepαπειες για τη χρονια νεφρικη ανεπαρκεια χρησιμοποιωντας ανταγωνιστες των ενσωματινων
ATE544453T1 (de) Kombinationstherapien mit l-fmau zur behandlung von hepatitis-b-virus-infektionen
MA55781A (fr) Polythérapies comprenant de l'aprémilast et des inhibiteurs de tyk2
ITRM20030442A0 (it) Composizione farmaceutica (stressen) per il trattamento di iperomocisteinemia.
TW200510447A (en) Novel fusidic acid derivatives
NO20065853L (no) Hydrogelinterferonformuleringer